Derivation and Validation of the Fungal Pneumonia Assessment and Likelihood Predictor Score
Key facts
- Who runs it
- Azienda Ospedaliero-Universitaria Careggi
- Where
- Italy1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Recruiting
- People taking part
- 400 people, planned
- Started
- 13 Nov 2025
- Expected to end
- 13 Nov 2031
- Type of study
- Observational, 2 groups
- Treatments tested
- FUNGAL-P Score Assessment
- Record updated
- 2 July 2026
Who can take part
- Age
- 18 years to 90 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 15 criteriaShow less
Who can take part
- Age ≥18 years and ≤90 years
- Presentation to the Emergency Department or hospital with pneumonia
- Pneumonia defined according to IDSA/ATS criteria as the presence of at least two clinical signs or symptoms of lower respiratory tract infection (temperature <36.0°C or >38.0°C, respiratory rate >20 breaths/min, oxygen saturation <90% on room air, arterial PaO₂ <60 mmHg, cough, sputum production, white blood cell count <4,000/μL or >10,000/μL, or bandemia >10%) together with radiographic evidence of a new pulmonary infiltrate or cavitary lesion
- Bronchoalveolar lavage (BAL), bronchial aspirate (BAS), or endotracheal aspirate (ETA) performed within 48 hours of hospital presentation
- Modified Rankin Scale score <5
- Availability of microbiological investigations for identification of fungal, bacterial, or viral pathogens
- Provision of informed consent, when required by applicable regulations and ethics committee approval
Who cannot take part
- Age <18 years or >90 years
- Refusal or withdrawal of informed consent
- Pregnancy
- Expected life expectancy <3 months
- Hospital-acquired pneumonia with onset >48 hours after hospital admission
- Modified Rankin Scale score ≥5
- Absence of microbiological diagnostic evaluation
- No identified bacterial, fungal, or viral pathogen after microbiological investigations
The main criteria, as questions
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 90 years old?
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The FUNGAL-P study is a single-center observational study designed to derive and validate a clinical prediction score for the early identification of fungal pneumonia in adult patients presenting with pneumonia.
Read full original descriptionShow less
The study includes a retrospective derivation cohort and a prospective validation cohort of patients undergoing microbiological evaluation of lower respiratory tract samples. Clinical, laboratory, radiological, microbiological, and treatment-related variables associated with fungal pneumonia will be analyzed to identify independent predictors of fungal infection. These predictors will be combined to develop the FUNGAL-P score.
The derived score will subsequently be evaluated in a prospective validation cohort to assess its diagnostic performance, calibration, and clinical utility. The ultimate goal is to facilitate earlier recognition of fungal pneumonia and support timely diagnostic testing and antifungal treatment in patients presenting to the Emergency Department or hospital with pneumonia.
The 2 groups in the trial
- Retrospective Derivation Cohort
Adult patients with microbiologically confirmed pneumonia enrolled at Careggi University Hospital between January 1, 2022 and December 31, 2023. Clinical, laboratory, radiological, microbiological, treatment, and outcome data were collected to identify independent predictors of fungal pneumonia and to derive the FUNGAL-P clinical prediction score.
Treatment: FUNGAL-P Score Assessment
- Prospective Validation Cohort
Consecutive adult patients with pneumonia enrolled at Careggi University Hospital between 13 nov, 2025 and December 31, 2030. The cohort was used to prospectively evaluate the diagnostic performance, calibration, and clinical utility of the derived FUNGAL-P score without influencing clinical management.
Treatment: FUNGAL-P Score Assessment
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Criteria questions
- Built from NCT07681583, who can take part
- Record updated
- 2 July 2026